Compare RECT & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RECT | GTBP |
|---|---|---|
| Founded | 1997 | 1965 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 17.7M |
| IPO Year | 2023 | 2016 |
| Metric | RECT | GTBP |
|---|---|---|
| Price | $1.22 | $0.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.5K | ★ 472.8K |
| Earning Date | 03-20-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $0.26 |
| 52 Week High | $4.98 | $1.53 |
| Indicator | RECT | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 49.53 | 39.86 |
| Support Level | $1.06 | $0.27 |
| Resistance Level | $1.40 | $0.47 |
| Average True Range (ATR) | 0.16 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 43.59 | 36.39 |
Rectitude Holdings Ltd is principally involved in the provision of safety equipment, encompassing essential items such as personal protective clothing, hand gloves, safety footwear, and personal fall arrest systems (a system used to arrest an employee in a fall from a walking-working surface, usually consisting of a body harness, anchorage, and connector), portable fire extinguishers and traffic products such as rubber speed humps, wheel stops and wheel chocks. Additionally the company has added auxiliary products such as industrial hardware tools and electrical hardware required for construction sites.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.